UNSPSC 51281809: Mitoxantrone

This classification denotes an anthraquinone compound with the molecular formula C22H28N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BZ114NVM5P, chemically known as 9,10-anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9ci) but generally known as mitoxantrone, which bears US NIH Compound Identifier 4212. European Medicines Agency schedules Mitoxantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09012MIG.

UNSPSC 51281809 Mitoxantrone is a Commodity code nominally designating a specific chemotherapy drug, but recent state and local solicitations tagged with this code show little alignment with that pharmaceutical product. Instead, the opportunities posted under this code span a broader pharmaceutical and medical supply procurement landscape: the Seminole County, Florida IFB for naloxone and drug deactivation systems; the Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs; the City of Tampa's medical and first aid supplies bid for fire rescue operations; and the Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products. The issuing-body mix is diverse—county health departments, state human services agencies, municipal fire departments, and multi-state cooperative purchasing alliances. The work actually being bought ranges from emergency response pharmaceuticals (naloxone) to commodity generics and OTC supplies for healthcare and public-safety operations.

Recent activity spans Florida, Texas, and Minnesota. The most concrete current opportunity is Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and a two-year initial term plus one-year renewal option; the City of Tampa's IFB 26P00145, posted March 25, 2026, for medical and first aid supplies to the Fire Department with an estimated contract value of $700,000 and a March 13, 2026 response deadline, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount not to exceed $10,000; and the Minnesota MMCAP RFP S1070000015802, posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The code exhibits moderate recent activity but shows poor categorical fit to the nominal mitoxantrone chemotherapy classification.